13F History
Schedule 13D/G History
Other Reports

EVENTIDE ASSET MANAGEMENT, LLC - Significant Ownership

Signature - Title: Charlyne Devens - Investment Compliance Director
Location: Boston, MA
Summary: This page shows a list of all the recent SCHEDULE 13D/G filings made by EVENTIDE ASSET MANAGEMENT, LLC.

Significant Ownership of EVENTIDE ASSET MANAGEMENT, LLC

Sym	Company	Class	Ownership	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
BBNX	Beta Bionics, Inc.	Common Stock	11.32%	$73M		4.86M		Eventide Asset Management, LLC	Jan 31, 2025
AURA	Aura Biosciences, Inc.	Common Stock, $0.00001 par value per share	8.17%	$29.6M		4.08M		Eventide Asset Management, LLC	Dec 31, 2024
XMTR	Xometry, Inc.	Class A Common Stock, par value $0.000001 per share	6.72%	$80.8M		3.15M		Eventide Asset Management, LLC	Dec 31, 2024
ZNTL	Zentalis Pharmaceuticals, Inc.	Common Stock, $0.001 par value per share	6.28%	$9.04M		4.48M		Eventide Asset Management, LLC	Dec 31, 2024
MIRM	Mirum Pharmaceuticals, Inc.	Common Stock, par value $0.0001 per share	5.43%	$117M		2.61M		Eventide Asset Management, LLC	Dec 31, 2024
LXEO	Lexeo Therapeutics, Inc.	Common Stock, $0.0001 par value per share	3.73%	$3.28M		1.23M		Eventide Asset Management, LLC	Dec 31, 2024
NKTR	Nektar Therapeutics	Common Stock, $0.0001 par value	3.61%	$5.45M		6.65M		Eventide Asset Management, LLC	Dec 31, 2024
INZY	Inozyme Pharma, Inc.	Common Stock, par value $0.0001 per share	3.46%	$2.35M		2.22M		Eventide Asset Management, LLC	Dec 31, 2024

Showing 1 to 8 of 8 entries

Schedules 13D/G Reported by EVENTIDE ASSET MANAGEMENT, LLC:

Showing 0 to 0 of 0 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.